Donor lymphocyte infusions (DLIs) remain a major strategy to treat and prevent post-transplant relapse, with the highest response rate seen in chronic-phase chronic myelogenous leukemia (CML) (60–78%) [2,3,4,5,6].
Aug 12, 2024
People also ask
How successful is DLI?
How do you feel after a DLI?
Is donor lymphocyte infusion considered transplant?
What are the risks of DLI?
Jan 29, 2022 · Remission was achieved in 19 patients (48.7%). Median time from first DLI to remission was 4 months (0.7-7.3). Chemotherapy was administrated in ...
Oct 12, 2023 · Results: Overall survival in all patients after DLI treatment was 59% at 2 years and 20% at 5 years. Relapse-free survival in patients in CR ...
Previous investigations in the RIC setting have shown that the rate of patients achieving full donor chimerism (FDC) after DLI ranges from 37% to 86% 11, 12, 13 ...
Jun 30, 2023 · The 6-year overall survival was 77% versus 32% (P = 0.03). Acute GvHD 2–4 occurred in 22% and half of the patients achieved mCR without any GvHD ...
Seventy-nine percent of patients ultimately received combination therapy, and overall survival at 2 years was 70%. Historial outcomes for patients with ...
Forty-nine percent of patients achieved complete remission (CR), with a median duration of remission of 6 months (range: 2-71+). CR rates were similar between ...
The donor lymphocyte infusion success rate varies depending on your health situation. Factors that affect the success of DLI include: How advanced the ...
Among all patients who received DLI, 87 (33%) survived more than 1 year after relapse; median survival was 7 months (range, 1 – 177 months). Cell-based therapy ...
Forty-nine percent of patients achieved complete remission (CR), with a median duration of remission of 6 months (range: 2-71+). CR rates were similar between ...
